Skip to main content
. 2015 Oct 20;27(1):185–192. doi: 10.1093/annonc/mdv501

Figure 1.

Figure 1.

Demographics of the patients examined for ALK fusions. One patient with iScore 3 had negative results for RT-PCR and the FISH analysis failed. However, the patient had positive FISH results outside this trial and was enrolled in another trial for crizotinib. In this study, this patient was assigned ‘not evaluable’ for the presence of ALK fusions (*), because the presence was confirmed outside the trial.